

Results for 6 months ended 30 November 2021

Steve McQuillan, CEO Stephen King, CFO



Financial highlights



Group Revenue

£45.1m (7.3)%

Gross Profit Margin

33.6% 2021 H1: 31.7%

Adjusted EBITDA

£5.8m 2021 H1: £5.8m

Adjusted Diluted EPS

10.0p 2021 H1 10.8p Dividend

2022 H1: 1.6p
Reinstated

Net Cash*


£22.7m 31 May 2021: £23.3m

Our divisions and brands




Engineered Pumps and Motors






Process Solutions and Rotating Equipment






Medical and Industrial Imaging











- ✓ Compelling Pinpoint-Invest-Exit (PIE) strategy
 - ✓ Niche market leadership positions
 - ✓ Consistent shareholder returns



Our proven strategy in action - Pinpoint



Strengthening the portfolio



- Magnetica compact helium-free MRI systems
- Adaptix compact 3D X-ray systems
- £4.0m now invested in Adaptix shares (11.9% of total)
- Initial markets are orthopaedic and veterinary.
- Businesses are collaborating on commercialisation of their complementary technologies



Our proven strategy in action - Invest



Establishing world class capability

Boothindustries

- Booth site rationalisation will complete this year
- Construction of new Bolton site extension completed
- New wing will eliminate surplus leased building
- Booth has a record orderbook and strong prospects
- Market research highlights international opportunities
- Aftermarket development is an emerging focus



Our proven strategy in action - Exit



Building and returning shareholder value

PB acquired for c£9m as part of HTG in 2017
Exit of PB for enterprise value of £35m in March 2021
Gross return on original capital investment almost 4X
3rd successful exit for Avingtrans since 2013





- Avingtrans is committed to profitable growth and to business exits at advantageous valuations.
- Proceeds can either be returned to shareholders, or redeployed for continued growth in shareholder value.
- Energy markets continue to be robust and M&A activity remains strong in this sector.
- We are confident about the current strategic direction and potential future Exit opportunities.





Divisional priorities - EPM



Hayward Tyler and Energy Steel

Markets

- Nuclear on-going life extension focus
 - Further contract wins in USA "life extension" market
 - Next Generation nuclear ITER project for ES confirmed
- Hydrocarbons progress still subdued by CV-19
 - Steady recovery underway
 - Focus on aftermarket, with 3rd party products targeted
- Defence more UK Government contracts won at HT Luton

Facilities

- New capex installed in Vermont;
- Energy Steel bedded-in at new smaller site
- Sale process for Luton site on-going Covid-19 induced delays
- **Products** building product portfolio with 3rd parties eg Ruhrpumpen



Divisional priorities - PSRE



Metalcraft, Fluid Handling, Ormandy, Booth, Composite Products

- Markets
 - Nuclear decommissioning (Metalcraft, Fluid Handling)
 - Sellafield phase 2 of 3M3 box contact won (£70m)
 - £4.4m Fluid Handling contract win for remote valves
 - Defence (Booth) further UK Government contracts in prospect
 - Infrastructure (Booth) rail and critical national infrastructure £36m HS2 contract underway
 - HVAC¹ (Ormandy) disrupted by CV-19, but orders continue to build
 - Composites focus on industrial customers
- Facilities site extension at Booth complete; Metalcraft training school will complete in 2022
- **Products** product range expansion at Booth. Tighter nuclear focus at Metalcraft



Metalcraft 3M3 box manufacture

Divisional priorities - MII



Magnetica, Scientific Magnetics. Tecmag Minority stake in Adaptix

- Medical Imaging
 - Integration of Magnetica has gone to plan
 - Compact MRI system progressing well
 - Convergent orthopaedic and veterinary focus
 - Initial addressable MRI market estimate c£400m
 - Bigger "pay per scan" opportunity targeted
 - Plans on track, albeit with some supply chain issues
 - Minority £4.0m investment in Adaptix (3D X-ray)
- NMR steady progress on Tecmag spectrometer sales and service
- Science niche magnet & cryogenic product sales continue, into selected markets







Financial Highlights

Interim results



£m	H1 FY22	H1 FY21	FY21
Revenue	45.1	48.7	98.5
Gross Profit %	15.2 33.6%	15.4 31.7%	29.9 30.4%
Adjusted EBITDA Adjusted EBITDA %	5.8 12.9%	5.8 12.0%	12.5 12.7%
Adjusted Profit before tax Adjusted Profit after tax	3.5 3.2	3.7 3.5	7.7 7.3
Adj. Diluted EPS (pence) Adj. Diluted EPS (pence)	10.0	10.8	22.4
excl. losses attributable to NCI	10.7	10.8	22.9

Results presented above are from continuing operations

Divisional Results



	Energy: I	Energy:			1H I	Energy: I	Energy:			1H
	EPM	PSRE N	/ledical	Central	FY22	EPM	PSRE I	Medical	Central	FY21
	£'m	£'m	£'m	£'m	£'m	£'m	£'m	£'m	£'m	£'m
Revenue:										
OE	6.1	20.5	8.0	-	27.4	7.5	17.3	4.4	-	29.2
AM	16.5	1.2	-	-	17.7	18.5	1.0	-	-	19.5
Total Revenue	22.6	21.7	0.8	-	45.1	26.0	18.3	4.4	-	48.7
Operating profit/(loss) Adjustments:	1.4	2.7	(0.5)	(0.5)	3.1	1.3	1.9	0.1	(0.5)	2.8
Acquisition costs/SBP	_	_	_	0.1	0.1	_	_	_	0.1	0.1
Restructuring costs	0.1	-	-	-	0.1	0.6	0.1	0.0	-	0.6
Amortisation of acquired intangibles	0.4	-	-	-	0.4	0.5	0.0	-	-	0.5
Adjusted EBIT	1.9	2.7	(0.5)	(0.4)	3.7	2.4	2.0	0.1	(0.5)	4.0
Depreciation and amortisation	1.3	0.6	0.3	-	2.1	1.1	0.5	0.2	-	1.8
Adjusted EBITDA	3.2	3.3	(0.2)	(0.4)	5.8	3.5	2.5	0.3	(0.5)	5.8
Adjusted EBITDA %	14.1%	15.2% ((26.6)%		12.9%	13.5%	13.8%	6.5%		12.0%


Balance Sheet



	H1 FY22	H1 FY21	FY21
	£'m	£'m	£'m
Tangible fixed assets	25.0	32.3	25.3
Goodwill	21.2	23.5	21.2
Investments	2.5	-	-
Other intangible	14.5	13.2	14.5
Deferred tax asset & pension surplus	3.1	3.0	3.1
Working capital	23.2	23.2	21.3
Provisions	(1.7)	(5.3)	(1.7)
Tax asset	0.3	0.5	-
Net cash / (debt)	20.0	(15.9)	20.3
Creditors > 1 year	(1.2)	(1.5)	(1.3)
Deferred tax liability	(4.1)	(2.2)	(3.5)
Net assets	102.8	70.8	99.0
Net cash / (debt) to equity	19.4%	(22.4)%	20.5%

Movement in Net Cash (£'m)






Impact of IFRS 16* - predominantly represents operating leases on premises which following the adoption of IFRS 16 are treated as lease liabilities (debt).

Dividend growth







Summary

Summary



- √ H1 FY22 on target to deliver full year expectations despite covid-19 disruptions
- ✓ Revitalisation of Hayward Tyler, Energy Steel and Booth remains on plan
- ✓ Order book: robust notwithstanding some contract delays.
 - ✓ Significant Nuclear sector contract wins in the UK and USA,
 - ✓ Sellafield 3M3 box project now worth £70m and moves to volume production phase
 - ✓ Exciting potential for Medical in compact, helium-free MRI system applications
- ✓ Strong balance sheet net cash of £22.7m in H1 in line with expectations
- ✓ PIE strategy (Pinpoint-Invest-Exit) for organic growth and added value through M&A
 - ✓ Magnetica integration proceeding to plan and £4.0m investment in Adaptix completed.
 - ✓ Exit of HT Luton site hampered by Covid-19, but continuing to pursue
- ✓ Interim dividend reinstated, at 1.6 pence
- ✓ Outlook: we remain vigilant, but confident about our strategy and prospects



Appendix



Pinpoint-Invest-Exit (PIE)

- Strong balance sheet
- Seasoned board and management
- Creating significant shareholder value

Our locations and employees (30 November 2021) Avingtrans







Our values

A High Performance Business



Integrity

We mean what we say and do what we say we will do, with respect for all concerned



Quality

Right first time, on time. Our products and services have enduring value to our customers



Agility

We adapt rapidly and cost effectively – in response to changes in the environment

Environment, Social and Governance (ESG) / Avingtrans

 Our goal is to ensure sustainability is embedded into our pinpoint-invest-exit business strategy. In 2021, we have reassessed our approach to sustainability, aligning ourselves with the UN's Sustainable Development Goals (SDGs). We consider the following to be our priorities:

Development of new technologies

- Development of new pumps for Small Modular Reactors (SMRs), Nuclear Fission (ITER project), and Molten Chloride Fast Reactors (MCFRs)
- Adapting existing fossil-fuel technologies for concentrated solar power (CSP)
- Going helium-free in our new compact MRI units
- Development of storage vessels for intermediate level waste from Sellafield power station







Operational eco-efficiency

- Supporting sites to achieve the ISO 14001 Environmental Management accreditation
- Installation of LED lighting to reduce energy consumption and create a safer working environment
- Completion of new facility at Booth site, built with thermal, lighting and energy saving advances.
- Establishment of Streamlined Energy and Carbon Reporting (SECR)








Health, safety and wellbeing

- Creation of covid-19 safe workplaces by taking measures such as:
 - Shielding of vulnerable employees
 - Factory and office re-layouts
 - Enhanced cleaning and site hygiene
- Supporting sites to achieve the ISO 45001 Health and Safety accreditation
- Board level oversight including site inspections








Market capitalisation progression (£m)





Blue chip partnerships





























M&A – successful exits



Brand	Acquisitions	Bought for £m ¹	Sold for £m ¹
JENA W//ATEC	JRT Ltd JenaTec Inc JGWT GMBH Boneham & Turner Moss Group	4.0 (FY02 - FY09)	14.5 (FY13)
Sigma a local sourceto a global capability	Sigma Components B&D Patterns C&H Composites Eng Group Aerotech Tubes PFW Farnborough RMDG Rolls Royce Nuneaton Rolls Royce Xi'an	22.0 (FY07 - FY16)	65.0 (FY16)
	Peter Brotherhood	9.3 (FY18)	35.0 (FY21)
- Enterprise Value			

Largest investors



Ordinary shares of 5p each	Number of shares (000s)	% of total shares
Harwood Capital	4,034	12.6%
Funds managed by Business Growth Fund	2,363	7.4%
Funds managed by Unicorn Asset Management Ltd	1,946	6.1%
R S McDowell's Pension Fund	1,406	4.4%
Funds managed by JTC Employer Solutions Trustee Limited	1,169	3.6%
P McDowell's Pension Fund	1,053	3.3%
Funds managed by Close Brothers Management	1,043	3.2%
Funds managed by Threadneedle Investments	1,039	3.2%
LGT Bank	973	3.0%

Shows the position at 30 November 2021